Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The era of monoclonal antibody-based therapeutics has arrived. Monoclonal antibodies of high quality targeting almost any antigen can now be engineered and manufactured in large quantities. In the clinic, monoclonal antibodies are proving to be safe and effective for the treatment of a wide range of diseases including rheumatoid arthritis, Crohn's disease, spondyloarthropathies, psoriasis and allograft rejection.

Original publication

DOI

10.1016/s0958-1669(02)00355-5

Type

Journal article

Journal

Current opinion in biotechnology

Publication Date

12/2002

Volume

13

Pages

615 - 620

Addresses

Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, W6 8LH, London, UK. evangelos.andreakos@ic.ac.uk

Keywords

Humans, Arthritis, Rheumatoid, Crohn Disease, Autoimmune Diseases of the Nervous System, Autoimmune Diseases, Inflammation, Antibodies, Monoclonal, Immunotherapy, Active, Drug Approval, Graft Rejection, Child, Clinical Trials as Topic